BioSpace News Archive

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a business update and reported financial results for the first quarter of 2024.

BriaCell Therapeutics Corp. today announced it has entered into securities purchase agreements with healthcare-focused institutional investors and a certain existing investor and a director of the Company for the purchase and sale of 2,402,935 common shares.

Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as...

iCAD, Inc. today reported its financial and operating results for the three months ended March 31, 2024.

Reviva Pharmaceuticals Holdings, Inc. today announced an enrollment update to the ongoing 1-year open-label extension (OLE) study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia.

Ractigen Therapeutics today announces that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for the initiation of Phase 1 clinical trials in China for RAG-17, targeting Amyotrophic Lateral Sclerosis (ALS).

CASI Pharmaceuticals, Inc. announced today the following: On April 12, 2024 CASI submitted the IND application to the FDA for CID-103 to support a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP).

BioAge Labs, Inc. today announced the formation of its Scientific Advisory Board (SAB).

Aspen Neuroscience, Inc. has received a CLIN2 grant award of $8 million from the California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, to support clinical research aimed at treating Parkinson’s disease (PD).

Teva Pharmaceutical Industries Ltd. today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company’s manufacturing and supply division, effective June 3, 2024.